Compositions Containing Cyclic Peptides And Methods Of Use

Abstract

The invention relates generally to cyclic peptides and their use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said cyclic peptides.

1 . Composition for topical use comprising one or more cyclic peptides and one or more topically acceptable vehicles. 
     
     
         2 . Composition according to  claim 1 , wherein said cyclic peptide is a homodetic cyclic peptide. 
     
     
         3 . Composition according to  claim 1 , wherein said cyclic peptide comprises one or more non-naturally occurring amino acids. 
     
     
         4 . Composition according to  claim 1 , wherein said cyclic peptide is comprised of 4 to 30 amino acids, selected from the group consisting of naturally occurring amino acids and on-naturally occurring amino acids. 
     
     
         5 . Composition according to  claim 1 , wherein said cyclic peptide comprises the Arg-Gly-Asp sequence. 
     
     
         6 . Composition according to  claim 1 , wherein said cyclic peptide is a compound according to formula I, 
       
         
           
                 
                 
               
                     
                   Cyclo-(Arg-Gly-Asp-Ω) I, 
                 
             
                
               
            
           
         
       
       wherein
 Ω is an amino acid subsequence comprised of one or more amino acids selected from the group consisting of the L- and D-forms of hPro, Ahds, Aos, Nhdg, Acha, Alb, Acpa, Tle Gly, Ala, 13-Ala, Asn, Asp, Asp(OR), Arg, Cha, Cys, Gln, Glu, His, Ile, Leu, Lys, Lys(Ac), Lys(AcNH 2 ) Lys(AcSH), Met, Nal, Nle, Orn, Phe, 4-Hal-Phe, homo-Phe, Phg, Pro, Pya, Ser, Thr, Tia, Tic, Trp, Tyr or Val, 
 and the N-alkyl derivatives thereof, 
 wherein 
 R is alkyl having 1-18 carbon atoms, 
 Hal is F, Cl, Br, I, 
 Ac is alkanoyl having 1-10 carbon atoms, aroyl having 7-11 carbon atoms or aralkanoyl having 8-12 carbon atoms, 
 
       and the salts and solvates thereof. 
     
     
         7 . Composition according to  claim 1 , wherein said one or more cyclic peptides comprise Cyclo-(Arg-Gly-Asp-DPhe-Acha), and/or a salt or solvate thereof. 
     
     
         8 . Composition for topical use comprising
 i) one or more cyclic peptides as described in  claim 1 ,   ii) one or more skin-tolerated and/or hair tolerated vehicles, and   iii) optionally one or more further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action, preferably having a skin-care and/or inflammation-inhibiting action.   
     
     
         9 . Composition according to  claim 1 , wherein said one or more cyclic peptides are contained in said composition in an amount of 0.00001 percent by weight to 10 percent by weight. 
     
     
         10 . Composition comprising one or more cyclic peptides as described in  claim 1 , and at least one further skin-care ingredient and at least one carrier which is suitable for topical applications. 
     
     
         11 . Composition according to  claim 10 , comprising the further skin-care ingredient ectoine, preferably in an amount of 0.01 to 10 percent by weight, more preferably 0.1 to 5 percent by weight and especially 0.1 to 2 percent by weight. 
     
     
         12 . Use of one or more cyclic peptides as described in  claim 1  for the manufacture of a cosmetic composition. 
     
     
         13 . Use of one or more cyclic peptides as described in  claim 1  for the preparation of a composition which is suitable for the prophylaxis and/or treatment of skin diseases which are associated with defective keratinisation relating to differentiation and cell proliferation, in particular for the treatment of acne vulgaris, acne comedonica, polymorphic acne, acne rosaceae, nodular acne, acne conglobata, age-related acne, acne occurring as a side effect, such as acne solaris, medicament-related acne or acne professionalis, for the treatment of other defects of keratinisation, in particular ichthyosis, ichthyosiform states, Darier's disease, keratosis palmoplantaris, leukoplakia, leukoplakiform states, skin and mucosal (buccal) eczema (lichen), for the treatment of other skin diseases which are associated with defective keratinisation and have an inflammatory and/or immunoallergic component, and in particular all forms of psoriasis relating to the skin, mucous membranes and finger- and toenails, and psoriatic rheumatism and skin atopy, such as eczema, or respiratory atopy, or also hypertrophy of the gums. 
     
     
         14 . Use of a one or more cyclic peptides as described in  claim 1  for the care, preservation or improvement of the general state of the skin or hair. 
     
     
         15 . Use of a one or more cyclic peptides as described in  claim 1  for the prophylaxis against or reduction of skin unevenness, such as wrinkles, fine lines, rough skin or large-pored skin. 
     
     
         16 . Use of one or more cyclic peptides as described in  claim 1  for the prophylaxis against time- and/or light-induced ageing processes of the human skin or human hair, in particular for prophylaxis against dry skin, wrinkle formation and/or pigment defects, and/or for the reduction or prevention of the harmful effects of UV rays on the skin. 
     
     
         17 . Medicinal product, comprising one or more cyclic peptides as described in  claim 1 , and one or more carriers and/or excipients. 
     
     
         18 . Composition, comprising
 i) 0.0001 to 20% by weight of Cyclo-(Arg-Gly-Asp-DPhe-Aeha), and/or a salt thereof,   ii) 0.001 to 50% by weight of one or more lipids.   
     
     
         19 . Composition, comprising
 i) 0.0001 to 20% by weight of Cyclo-(Arg-Gly-Asp-DPhe-Acha), and/or a salt thereof,   ii) 0.001 to 50% by weight of one or more lipids, and   iii) 10 to 99.9979% by weight of water, and optionally   iv) 0.001 to 20% by weight of et least one further ingredient, selected from the group consisting of ectoin, biotin, taurine, caffeine, taurine, purine, and/or dervatives thereof.   
     
     
         20 . Composition according to  claim 18 , wherein the one or more lipids are selected from the group consisting of lecithin, spingomyelin, dipalmitoyl lecithin, distearoylphosphatidylcholine, phosphatidylcholine, saturated phosphatidylcholine and unsaturated phosphatidylcholine, and mixtures and salts thereof. 
     
     
         21 . Composition, comprising
 i) one or more cyclic peptides as described in  claim 1 ,   ii) one or more lipids,   iii) one or more physiologically acceptable solvents, and optionally   iv) one or more further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action.   
     
     
         22 . Use of a composition according to  claim 18 , for the manufacture of a topical composition, cosmetic composition, pharmaceutical composition and/or a medicinal product. 
     
     
         23 . Use according to  claim 22 , wherein the composition is applied in the manufacture in an amount of 0.0001 to 50% by weight, based on the total weight of the topical composition, cosmetic composition, pharmaceutical composition and/or medicinal product. 
     
     
         24 . Topical composition, cosmetic composition, pharmaceutical composition and/or medicinal product, comprising 0.0001 to 50% by weight of a composition according to  claim 18 , based on the total weight of said topical composition, cosmetic composition, pharmaceutical composition and/or medicinal product. 
     
     
         25 . A method for the manufacture of a composition comprising
 a) providing a composition according to  claim 18 ,   b) providing one or more topically acceptable vehicles, and optionally   c) providing one or more further active compounds having a skin-care, hair-care and/or inflammation-inhibiting action,   d) and blending, mixing and/or homogenising a) and b), and optionally c), in any order.   
     
     
         26 . Composition for topical use characterized in that it contains 0.0001 to 50% by weight, based on the total weight of said composition for topical use, of a cyclic peptide containing composition according to  claim 18 .